Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Multiple Endogenous Signaling Pathways refers to the integrated networks of molecular interactions, such as the MAPK/ERK or PI3K/Akt pathways, that transmit external stimuli to elicit specific cellular responses (National Human Genome Research Institute, 2024). These pathways are essential for maintaining homeostasis and regulating fundamental biological processes including growth, metabolism, and apoptosis (Cooper, 2000). Because this term represents a broad category of biological activity rather than a discrete molecular entity like a receptor or enzyme, it is not classified as a specific therapeutic target (Santos et al., 2017). In drug development, specificity is required to ensure that a molecule interacts with a defined target to produce a predictable clinical outcome (Overington et al., 2006). Consequently, while multiple pathways may be dysregulated in complex diseases like cancer or chronic inflammation, therapeutic intervention focuses on modulating specific components within these networks to improve efficacy and reduce systemic toxicity.
Not applicable as this is a collective term for various biological processes rather than a single drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple Endogenous Signaling Pathways.